Subcutaneous Cinqair results add to Teva's troubles

23 January 2018

Hopes that Teva Pharmaceutical Industries (NYSE: TEVA) might be able to steal a march over its rivals in the asthma space were all but dashed on Monday.

The Israeli drugmaker, which announced a major restructuring and job cuts after a challenging 2017, reported that a Phase III trial evaluating subcutaneously administered Cinqair (reslizumab) in a pre-filled syringe did not meet its primary endpoint of significantly reducing clinical asthma exacerbations (CAEs) in patients with uncontrolled asthma and elevated blood eosinophils.

A support study, also evaluating the subcutaneous version of the drug, in patients with oral corticosteroid (OCS)-dependent asthma, failed to meet its primary endpoint of reduction in daily OCS dose.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK